Your browser is no longer supported. Please, upgrade your browser.
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own0.50% Shs Outstand119.12M Perf Week-1.96%
Market Cap118.04M Forward P/E12.50 EPS next Y0.08 Insider Trans0.00% Shs Float116.88M Perf Month0.00%
Income-36.70M PEG- EPS next Q-0.07 Inst Own25.40% Short Float4.22% Perf Quarter-20.63%
Sales3.10M P/S38.08 EPS this Y29.60% Inst Trans-0.03% Short Ratio4.91 Perf Half Y-20.00%
Book/sh-0.30 P/B- EPS next Y126.70% ROA-49.00% Target Price- Perf Year-43.50%
Cash/sh0.47 P/C2.13 EPS next 5Y- ROE82.90% 52W Range0.75 - 2.94 Perf YTD-19.35%
Dividend- P/FCF- EPS past 5Y3.00% ROI120.80% 52W High-66.59% Beta0.80
Dividend %- Quick Ratio3.80 Sales past 5Y-22.40% Gross Margin-70.90% 52W Low30.96% ATR0.04
Employees25 Current Ratio3.90 Sales Q/Q-86.20% Oper. Margin- RSI (14)38.61 Volatility2.88% 3.88%
OptionableYes Debt/Eq- EPS Q/Q-1.00% Profit Margin- Rel Volume0.75 Prev Close1.00
ShortableYes LT Debt/Eq- EarningsAug 16 AMC Payout- Avg Volume1.00M Price0.98
Recom2.00 SMA20-3.72% SMA50-6.68% SMA200-32.40% Volume755,721 Change-1.78%
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Oct-04-21 07:30AM  
Sep-10-21 03:19PM  
Aug-30-21 05:10PM  
08:30AM  
Aug-26-21 08:30AM  
Aug-19-21 07:07AM  
Aug-16-21 05:25PM  
04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 04:30PM  
01:30PM  
10:16AM  
10:00AM  
09:25AM  
08:30AM  
12:20AM  
Aug-08-21 01:00PM  
Aug-07-21 02:35PM  
Aug-06-21 09:33PM  
07:15PM  
02:30PM  
01:03PM  
01:00PM  
12:15PM  
10:00AM  
Aug-05-21 11:25AM  
Aug-04-21 08:00PM  
12:00PM  
11:20AM  
11:05AM  
10:00AM  
01:17AM  
Aug-03-21 10:45PM  
12:00PM  
11:18AM  
Aug-02-21 10:24PM  
03:01PM  
01:05PM  
12:30PM  
11:00AM  
10:33AM  
Jul-31-21 11:00AM  
Jul-30-21 07:23PM  
07:10PM  
Jul-29-21 12:45PM  
12:45PM  
10:00AM  
Jul-28-21 08:00PM  
07:18PM  
11:00AM  
Jul-27-21 11:15AM  
11:00AM  
Jul-26-21 10:03PM  
03:12PM  
02:00PM  
01:00PM  
Jul-25-21 11:00AM  
Jul-23-21 08:49PM  
01:30PM  
Jul-22-21 11:00AM  
Jul-21-21 09:30PM  
08:00PM  
01:05PM  
11:05AM  
Jul-20-21 07:15PM  
01:40PM  
01:00PM  
11:30AM  
10:00AM  
Jul-19-21 07:45PM  
04:00PM  
02:45PM  
01:05AM  
Jul-18-21 09:40AM  
09:35AM  
Jul-17-21 12:20PM  
Jul-16-21 05:20PM  
Jul-15-21 06:10PM  
02:20PM  
01:43PM  
Jul-14-21 09:00PM  
11:02AM  
09:28AM  
08:30AM  
Jul-13-21 07:50PM  
01:00PM  
11:30AM  
11:00AM  
11:00AM  
Jul-12-21 01:00PM  
01:00PM  
Jul-11-21 11:55PM  
Jul-10-21 11:45AM  
07:10AM  
Jul-08-21 05:34PM  
11:30AM  
10:00AM  
Jul-07-21 11:00PM  
08:29PM  
10:30AM  
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Hayward, California.